Printer Friendly

SMITHKLINE BEECHAM AND HUMAN GENOME SCIENCES ANNOUNCE COLLABORATION FOR LARGE SCALE GENE SEQUENCING

 Applications of Genomic Research for the Development of Pioneer
 Medicines, Vaccines and Diagnostic Products
 PHILADELPHIA, May 20 /PRNewswire/ -- SmithKline Beecham (NYSE: SBH) (SB) and Human Genome Sciences (HGS) today announced the formation of a strategic alliance to collaborate in large scale gene sequencing, which seeks to identify the structure and function of human genes in health and disease.
 The goal of this alliance is to convert genomic data into pioneer drugs and diagnostic products and services.
 Under the terms of the agreement, SB will receive exclusive worldwide rights to therapeutic, vaccine and diagnostic products and services developed from gene sequence data identified by the collaboration.
 "HGS was founded to become a leader in converting genomic data into useful healthcare products," said William A. Haseltine, Ph.D., chairman and chief executive of HGS. "It represents one of the largest gene discovery groups in the world devoted to discovering the biological function of unique genes."
 Dr. George Poste, chairman, Research and Development, SB Pharmaceuticals, said, "These gene sequences will provide critical new insights into the genetic alterations responsible for major human diseases and identify with great precision the molecular changes in body function that provide targets for new classes of drugs and vaccines."
 Genetic sequence information will also produce increasingly accurate molecular tests for the early detection of disease, including the identification of people at risk even before disease has begun.
 Dr. Poste stated, "Molecular diagnostics have the potential to be a key component in lowering healthcare costs. Earlier diagnosis of serious diseases will permit earlier and more effective treatment, with resulting economic benefits for both patients and society."
 "Over the coming decade the use of these new molecular diagnostic tests will create a major change in healthcare delivery by shifting the emphasis to disease prediction and prevention rather than reliance on treatment alone," he continued.
 Dr. Poste emphasized that the alliance with HGS will strengthen the already substantial internal biotechnology capacity of SB's pharmaceutical, vaccine and diagnostics businesses.
 "It places SB at the forefront of molecular genetics, which is fundamental for future success in the development of innovative new products for the detection, prevention and treatment of human disease," he said.
 The agreement between SB and HGS also includes applications for development of body imaging products, devices and biosensor technology, plus applications for computing and animal health.
 HGS will receive royalties on sales of products in the human and animal health fields, will be able to co-promote certain products, and retains the rights to the use of genetic data for applications in gene therapy and the design of antisense agents. In addition, HGS can develop certain human and animal health product opportunities which SB elects not to pursue.
 SB and HGS recognize the commercial and humanitarian importance of the scientific data emerging from this collaboration, and the intent is to maximize its potential as rapidly as possible. Data outside SB or HGS' areas of interest will be made available to third parties on a fair and equitable basis.
 The Human Genome
 The human genome contains all the genetic information for human life. It is composed of approximately 100,000 pairs of genes, arranged on 46 chromosomes.
 Each gene is an individual unit of heredity and contains a "code" enabling body cells to produce a specific collection of proteins that control the functions of the several hundred different cell types in the body.
 Genes control the codes that structure and regulate the way body cells and tissues develop and function. Changes in gene structure or their regulation result in the development of disease.
 Genes are composed of deoxyribonucleic acids (DNA). These sequences exist in numerous combinations, the so-called genetic code. Identifying and differentiating the codes expressed by different cells and the subtle changes that occur in disease are the key to understanding the genome.
 Human Genome Sciences Inc., based in Rockville, Md., is a company devoted to converting genomic data into useful healthcare products for diagnosis and treatment of human and animal diseases. It was created in 1992 by Healthcare Investment Corp., the largest venture capital fund in the world exclusively devoted to healthcare.
 SmithKline Beecham -- one of the world's leading healthcare companies -- discovers, develops, manufactures and markets human and animal pharmaceuticals, over-the-counter medicines and health related consumer products and clinical laboratory services.
 /delval/
 -0- 5/20/93
 /CONTACT: Jeremy Heymsfeld (media), 215-751-5166, or Richard Williams (investors), 215-751-7002, both of SmithKline Beecham, or William A. Haseltine of Human Genome Sciences, 301-251-6000, or Wallace Steinberg of Healthcare Investment Corp., 908-906-4605/
 (SBH)


CO: SmithKline Beecham; Human Genome Sciences Inc.; Healthcare
 Investment Corp. ST: Pennsylvania, Maryland IN: MTC SU: JVN


MP -- PH003 -- 0604 05/20/93 08:59 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 20, 1993
Words:774
Previous Article:ASHLAND REFINERY UNIT BACK IN OPERATION; OTHER REPAIRS WILL NOT CAUSE GASOLINE PRODUCTION PROBLEMS
Next Article:MARTECH USA ANNOUNCES $54-MILLION CONTRACT TO BUILD MILITARY HOUSING
Topics:


Related Articles
SMITHKLINE BEECHAM, HUMAN GENOME SCIENCES, AND MERCK KGAA SIGN MEMORANDUM OF INTENT FOR GENOMICS AGREEMENT
SCHERING-PLOUGH, HUMAN GENOME SCIENCES AND SMITHKLINE BEECHAM SIGN GENOMICS COLLABORATION AGREEMENT
SCHERING-PLOUGH, HUMAN GENOME SCIENCES SIGN GENE THERAPY COLLABORATION AGREEMENT
SMITHKLINE BEECHAM AND HUMAN GENOME SCIENCES SIGN GENOMICS COLLABORATION AGREEMENT WITH SYNTHELABO
HGS/TIGR Funding Relationship Reaches Early Conclusion
Hyseq and SmithKline Beecham Clinical Laboratories Conclude Initial Relationship; Companies to Consider Future Opportunities
Human Genome Sciences and Affymetrix Announce Agreement to Develop Bacterial GeneChip(R) Probe Arrays
Sangamo BioSciences Signs Agreement With SmithKline Beecham.
Sangamo BioSciences Announces Collaborative Research Agreement With Immunex Corporation.
Affymetrix to Participate in New Mouse Genome Consortium.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters